Trials / Completed
CompletedNCT05067881
Post-COVID-19 Pneumo-hematocele
Post COVID-19 Pneumo-hematocele: Clinical Presentation and Treatment Pathway
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- Hospital General Ajusco Medio · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Introduction. As the COVID-19 pandemic has continued, an increasing number of long-term complications are emerging. Recently, the appearance of characteristic pulmonary lesions has been noted, being described as post COVID-19 pneumatocele. The aim of this study is to describe the clinical, histopathologic and imaging features of post COVID-19 pneumo-hematoceles (PHC) and secondarily to suggest a treatment algorithm in these patients. Methods. A retrospective study was performed in patients admitted with diagnosis of SARS-CoV2 infection from March 2020 to September 2021 who presented PHC on imaging studies. Clinical and demographic variables were recorded and CT scans were analyzed. A logistic regression analysis was performed to determine the risk for rupture according to PHC characteristics. It appears that PHC occurs secondary to encapsulation of blood accumulation, the result of micro capillary bleeding, with partial reabsorption of blood and subsequent air filling. The recommendation is to operate on patients with PHC of 5cm and those with persistent lesions of 3cm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Pulmonary resection | Resection of pneumohematocele |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2020-03-01
- Completion
- 2021-09-20
- First posted
- 2021-10-05
- Last updated
- 2021-10-05
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT05067881. Inclusion in this directory is not an endorsement.